BioMedNewsBreaks — VERAXA Biotech AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”) Announce $1.64 Billion Business Combination to Create Clinical-Stage Cancer Therapy Powerhouse
VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH) announced a definitive agreement to merge in a transaction that would value the combined company at approximately $1.64 billion. Upon closing, VERAXA is expected to trade on NASDAQ under the ticker symbol “VERX.” The company is advancing a proprietary Bi-Targeted Antibody Cytotoxicity (“BiTAC”) platform for dual-marker cancer therapeutics, including bispecific ADCs and T cell engagers, with a pipeline featuring nine programs and an active Phase 1 trial in leukemia. VERAXA is backed by majority shareholders Xlife Sciences AG (SIX: XLS), EMBL and EMBLEM,…